Results 291 to 300 of about 369,824 (381)

General Arithmetic

, 1927
Morgan Ward
openalex   +2 more sources

Styrene-Butadiene Rubber Latex Modified Mortars Prepared with High Early Strength Portland Cement. [PDF]

Materials (Basel)
Kligys M, Girskas G.
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Soticlestat (TAK‐935) is a cholesterol 24‐hydroxylase inhibitor. A physiologically‐based pharmacokinetic model has been developed to predict potential soticlestat drug–drug interactions (DDIs) using the Simcyp v20 Population‐based Simulator and verified with data from single‐/multiple‐rising‐dose and clinical DDI studies.
Hongxia Jia, T. Eric Ballard, Liming Zhang, Lawrence Cohen, Mackenzie C. Bergagnini‐Kolev, Ian E. Templeton, Hannah M. Jones, Wei Yin   +7 more
wiley   +1 more source

Achievement emotions in kindergarten: the association of solution accuracy with discrete joy, sadness, and surprise. [PDF]

Front Psychol
Kutaka TS, Chernyavskiy P, Hofkens T.
europepmc   +1 more source

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han, Paul Benn, Jörg Sievers, David Dorey, Michael Warwick‐Sanders, Randa Hareedy, Louise Harkness, Claudia Leemereise, Kjersten Offenbecker, Christina Donatti, Darin B. Brimhall, Christian Schwabe, Craig Boyle, Michael A. Hassman, Steve Knowles, Ronald D'Amico, William R. Spreen   +16 more
wiley   +1 more source

Periodontal diseases, potential mediators and development of liver fat content: a community-based large cohort. [PDF]

Front Med (Lausanne)
Liu B, Jia Y, Gu Z, Li Y, Zhou Y, Cao Y.
europepmc   +1 more source

Thermodynamic Insights on the Structure‐Property Relationships in Substituted Benzenes: Are the Pairwise Interactions in Tri‐Substituted Methyl‐Nitro‐Benzoic Acids Still Valid?

ChemPlusChem, EarlyView.
A comprehensive thermodynamic study of nine methyl‐nitro‐benzoic acids was carried out. By combining experimental, empirical and computational methods, a consistent and reliable set of phase transition enthalpies and enthalpies of formation was established.
José M. Silva Ferraz, Vladimir N. Emel'yanenko, Dzmitry H. Zaitsau, Artemiy A. Samarov, Bruno Brunetti, Andrea Ciccioli, Stefano Vecchio Ciprioti, Sergey P. Verevkin   +7 more
wiley   +1 more source

Early numerical skills and mathematical domains in autistic students in primary school. [PDF]

Front Psychiatry
Bejarano-Martín Á, Casado-Vara R, Magán-Maganto M, Díez E, Jenaro C, Flores N, Orrantia J, Canal-Bedia R.   +7 more
europepmc   +1 more source

The Chancellor's Arithmetic

Fiscal Studies, 1984
Devereux, M, Morris, N
openaire   +3 more sources

Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration

Clinical Pharmacology &Therapeutics, EarlyView.
Atazanavir has been reported to increase total serum bilirubin level up to ninefold. It is widely believed that the observed total bilirubin elevation is primarily due to UGT1A1 inhibition. However, UGT enzymes are well‐known as a low‐affinity and high‐capacity system, and the observed drug–drug interaction mediated by UGTs is usually less than twofold.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source